ClinicalTrials.gg
RecruitingNCT04749329Updated Oct 26, 2023

Use of Resorbable Prosthetic Mesh "Ante Rectus" as Prevention of Parastomal Hernia.

An interventional study of Mesh Group in Parastomal Hernia, sponsored by Azienda Sanitaria Locale Napoli 2 Nord. Recruiting at 2 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-10-26.

Sponsored by Azienda Sanitaria Locale Napoli 2 Nord · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2024, 2 years 3 months ago, but the record still lists the study as recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
110
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The aim of this study was to assess feasibility, potential benefits and safety of a prophylactic biosynthetic mesh placed at the time of colostomy.

Read the detailed description

Several surgical scenarios include colon diversion as part of their management. Among them, the most frequent conditions requiring colostomy are abdominal malignancies, large bowel diverticulitis, Inflammatory Bowel Disease, bowel obstruction or perforation and postoperative complications such as anastomotic leakage. Colostomy related morbidity includes retraction, infection, prolapse, skin problems and parastomal hernia. Parastomal Hernia is a quite common late complication, with a clinical rate up to 55%, reaching 80% when assessed by Computer Tomography. Although Parastomal Hernia is often asymptomatic, significant morbidity exists, including pain, intermittent obstruction, stoma leakage, skin irritation and pouching, often reducing patients' Quality of Life. Several surgical options are available for Parastomal Hernia repair, many of them supporting the use of mesh to strengthen the fascia. However, results are often disappointing with quite high recurrence rates, rising up to 33%, even with the use of a mesh. Several studies have been published, testing effectiveness and safety of a prophylactic mesh in vertical laparotomy closure to prevent incisional hernia.

The aim of this study was to assess feasibility, potential benefits and safety of a prophylactic biosynthetic mesh placed at the time of colostomy.

02

Conditions studied

  • Parastomal Hernia
03

In context

Lead sponsor

Azienda Sanitaria Locale Napoli 2 Nord is the lead sponsor of 16 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • age > 18 years
  • endo colostomy

Exclusion criteria

Exclusion Criteria:

  • age \< 18 years;
  • \< 24 months (as estimated by the operating surgeon)
  • pregnancy
  • therapy within 2 weeks before surgery
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
110 participants (estimated)

Study arms

  • No intervention
    Control Group

    no mesh was used for end colostomy fashions

  • Experimental
    Mesh Group

    Mesh of Bio A was used for end colostomy fashions

    Device: Mesh Group

Interventions

  • DeviceMesh Group

    All MG patients underwent the procedure with ante rectus positioned prophylactic mesh according to the following standardized technique. A BIO-A circular-shaped mesh measuring 8X10 cm in diameter is prepared with an internal 2 cm hole to let the bowel pass. An at least 8x8 cm space is created between the anterior rectus sheath and the rectus abdominis muscle and, then, the mesh is positioned. The bowel is passed through the rectus muscle via the circular incision in the middle of the mesh. Single absorbable monofilament sutures anchored the mesh laterally in the ante rectus pocket, while medially the mesh is fixed with four stitches to the colon and to both the anterior rectal sheet. The stoma is attached to the skin similarly to CG patients.

06

What researchers measure

Primary outcomes

  1. Rate of Parastomal Hernia at clinical control.

    Detect of paratoia hernia

    Time frame: 3 months

  2. Rate of Parastomal Hernia at clinical control.

    Detect of paratoia hernia

    Time frame: 6 months

  3. Rate of Parastomal Hernia at clinical control.

    Detect of paratoia hernia

    Time frame: 12 months

  4. Rate of Parastomal Hernia at clinical control.

    Detect of paratoia hernia

    Time frame: 24 months

Secondary outcomes

  1. Rate of Parastomal Hernia at tomography observation.

    detect of parastomal hernia

    Time frame: 3 months follow-up

  2. Rate of Parastomal Hernia at tomography observation.

    detect of parastomal hernia

    Time frame: 6 months follow-up

  3. Rate of Parastomal Hernia at tomography observation.

    detect of parastomal hernia

    Time frame: 12 months follow-up

  4. Rate of Parastomal Hernia at tomography observation.

    detect of parastomal hernia

    Time frame: 24 months follow-up

  5. Number of patients affected by Superficial surgical site infections

    Superficial infections according to Clavien-Dindo criteria

    Time frame: Within 30 days postoperatively

  6. Number of patients affected by Deep surgical site infections

    Deep surgical site infections according to Clavien-Dindo criteria

    Time frame: Within 30 days postoperatively

07

Study locations

1 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2024; primary completion for Aug 2024, 0 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 7, 2021
First posted
Feb 11, 2021
StartEst.
Aug 1, 2024
Primary completionEst.
Aug 1, 2024
CompletionEst.
Aug 1, 2024
Last update
Oct 26, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 26, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04749329
Lead sponsor
Azienda Sanitaria Locale Napoli 2 Nord
Responsible party
Francesco Pizza (Head of Bariatric Unit, Azienda Sanitaria Locale Napoli 2 Nord) — Principal investigator
First posted
Feb 11, 2021
Start date
Aug 1, 2024 (estimated)
Primary completion
Aug 1, 2024 (estimated)
Completion
Aug 1, 2024 (estimated)
Last update
Oct 26, 2023

Study contacts

Francesco Pizza, Md, PhD
Contact
francesco_pizza@libero.it
3338275449
Francesco Pizza, Md, PhD
Contact
francesco.pizza@laslnapoli2nord.it
3338275449
Francesco Pizza, Md, PhD
principal investigator · Azienda Sanitaria Locale Napoli 2 Nord

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion